July 2024 – Page 10

Innovent Achieves Another Phase 3 Victory in China for Next-Generation Lilly GLP-1 Drug

9 months ago talkbio0Tagged Biological Factors, China, Diabetes, Eli Lilly, Glucagon-Like Peptide 1, Innovent, mazdutide, Phase 3 trial, Weight Loss

Innovent Biologics, Lilly, GLP-1, Mazdutide, Phase 3 Trial, Type 2 Diabetes, Weight Loss, China

Grünenthal Expands US Presence with $250 Million Acquisition of Valinor Pharma and Movantik

9 months ago talkbio0Tagged Acquisition (action), Drug Industry, expansion, Grünenthal, Movantik, Pharma, Valinor

Grünenthal, Valinor Pharma, Movantik, Acquisition, US Expansion, Pharmaceutical Industry

Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns

9 months ago talkbio0Tagged agonists, China, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, semaglutide, tirzepatide, Wegovy, Weight Loss, Zepbound

Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy

George Church’s GRObio Secures $60 Million to Advance Gout Treatment into Clinical Trials

9 months ago talkbio0Tagged biotech, Clinical Trials, George Church, Gout, GRObio

GRObio, George Church, Gout Treatment, Clinical Trials, Biotech Funding

AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study

9 months ago talkbio0Tagged AVEO, Fotivda, Malignant neoplasm of kidney, Neoplasms, nivolumab, Phase 3 Clinical Trials, Renal Cell Carcinoma, tivozanib

AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer

Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo

9 months ago talkbio0Tagged Accelerated, Agenus, Antineoplastic Agents, Approved, BOT, BOT/BAL, Colorectal Carcinoma, stock selloff, United States Food and Drug Administration

Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff

J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure

9 months ago talkbio0Tagged Epilepsy, Johnson & Johnson, nervous system disorder, Phase 2 Clinical Trials, Receptors, Metabotropic Glutamate

Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders

PhRMA Intensifies Pricing Criticism, Targets Shared Ownership of Insurers and PBMs in New Ad

9 months ago talkbio0Tagged Insurance Carriers, Ownership, PBMs, PhRMA, Pricing

PhRMA, pricing attack, shared ownership, insurers, PBMs, new ad

FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search

9 months ago talkbio0Tagged Accelerated, Agenus, Approved, balstilimab, Botensilimab, Colorectal Carcinoma, Combined, Immunotherapy, Partnership, Phase 3 Clinical Trials, United States Food and Drug Administration

Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership

The Best Practice Organization: Key to Success in Today’s Biopharma Industry

9 months ago talkbio0Tagged Anthropological Culture, Best Practice Organization, Biopharma Industry, Business Development, commercial field teams, Generative AI, Leadership, Medical Affairs, Practice Experience, Strategic Workforce Planning, Success Factors, Talent Strategy

Biopharma Industry, Best Practice Organization, Success Factors, Operational Excellence, Business Development Strategy, Talent Strategy, Medical Affairs, Commercial Field Teams, Generative AI, Integrated Teams, Strategic Workforce Planning, Leadership, Culture, Team Dynamics, Talent Experience